+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets

  • ID: 4830107
  • Drug Pipelines
  • August 2019
  • Region: Global
  • 60 pages
  • VPA Research
1 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • bluebird bio Inc
  • Imara Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • Pfizer Inc
  • MORE
High levels of pipeline activity are being observed in Vaso-Occlusive Crisis Associated With Sickle Cell Disease treatment during 2019. Clinical development activities are being undertaken by more than 10 companies including AstraZeneca Plc, bluebird bio Inc, Global Blood Therapeutics Inc, Hillhurst Biopharmaceuticals Inc, Imara Inc and others.

A Significant contribution to the Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline included 12 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.

Increased understanding of underlying causes of Vaso-Occlusive Crisis Associated With Sickle Cell Disease condition and increased access to investments is encouraging growth of Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.

The research study is structured to provide clear and actionable insights into Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.

The report addresses the discovery, research and pre-clinical stage active Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.

The current report examines the current Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.

In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Vaso-Occlusive Crisis Associated With Sickle Cell Disease. Further, orphan drug status, fast track designation, grants awarded and other special status for Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline compounds are also included.

This study was produced independently by the publisher from their proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Vaso-Occlusive Crisis Associated With Sickle Cell Disease pipeline and formulate effective research and development strategies.

Research Methodology

Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.

Scope of the Research

Vaso-Occlusive Crisis Associated With Sickle Cell Disease Pipeline candidates
  • Pre-clinical Phase: Discovery, research, pre-clinical
  • Early Phase: Phase 1 and Phase 2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease drugs
  • Late phase: Phase 3 and in-approval Vaso-Occlusive Crisis Associated With Sickle Cell Disease drugs
Companies involved in the Pipeline
  • Company overview
  • Snapshot
  • Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic treatment activities
Details for each Vaso-Occlusive Crisis Associated With Sickle Cell Disease drug candidate
  • Snapshot
  • Drug Name
  • Alternative Names
  • Company
  • Originator
  • Phase
  • Molecule Type
  • Orphan Drug Status
  • Drug Overview
  • Mechanism of Action
  • Current Status
  • Trial Details
Other details
  • Pre-clinical trials for each drug candidate
  • Clinical trials for each drug candidate
Recent Vaso-Occlusive Crisis Associated With Sickle Cell Disease therapeutic candidates, clinical trials, investments, grants, partnerships, licenses, awards and other news
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca Plc
  • bluebird bio Inc
  • Imara Inc
  • Novartis AG
  • NuvOx Pharma LLC
  • Pfizer Inc
  • MORE
1.1 List of Tables
1.2 List of Figures

2 Executive Summary
2.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Disease Overview
2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pipeline Snapshot
2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pipeline Drugs by Phase
2.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pipeline Drugs by Company
2.5 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pipeline Drugs by Mechanism of Action

3 Company wise Pipeline Analysis
3.1 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.2 bluebird bio Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.3 Global Blood Therapeutics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.4 Hillhurst Biopharmaceuticals Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.5 Imara Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.6 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.7 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.8 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.9 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.10 Prolong Pharmaceuticals LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.11 Sancilio & Company Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019
3.12 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Pipeline, H2- 2019

4 Phase 1 Pipeline Drug Details
4.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 1 Drug Details
4.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 1 Drug Overview
4.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details

5 Phase 2 Pipeline Drug Details
5.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 2 Drug Details
5.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 2 Drug Overview
5.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details

6 Phase 3 Pipeline Drug Details
6.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 3 Drug Details
6.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 3 Drug Overview
6.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details

7 Pre-clinical Phase Pipeline Drug Details
7.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pre-clinical Phase Drug Details
7.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pre-clinical Phase Drug Overview
7.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details

8 Recent News and Developments

9 Appendix
9.1 About the Publisher
9.2 Sources and Research Methodology
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca Plc
  • bluebird bio Inc
  • Global Blood Therapeutics Inc
  • Hillhurst Biopharmaceuticals Inc
  • Imara Inc
  • Modus Therapeutics Holding AB
  • Novartis AG
  • NuvOx Pharma LLC
  • Pfizer Inc
  • Prolong Pharmaceuticals LLC
  • Sancilio & Company Inc
  • Seattle Genetics Inc
Note: Product cover images may vary from those shown
Adroll
adroll